Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study
The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1...
Gespeichert in:
| Veröffentlicht in: | PloS one 2009-04, Vol.4 (4), p.e5272-e5272 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e5272 |
|---|---|
| container_issue | 4 |
| container_start_page | e5272 |
| container_title | PloS one |
| container_volume | 4 |
| creator | Lingappa, Jairam R Kahle, Erin Mugo, Nelly Mujugira, Andrew Magaret, Amalia Baeten, Jared Bukusi, Elizabeth A Cohen, Craig R Katabira, Elly Ronald, Allan Kiarie, James Farquhar, Carey Stewart, Grace John Makhema, Joseph Essex, M Were, Edwin Fife, Kenneth Debruyn, Guy Gray, Glenda McIntyre, James Manongi, Rachel Kapiga, Saidi Coetzee, David Allen, Susan Inambao, Mubiana Kayitenkore, Kayitesi Karita, Etienne Kanweka, William Delany, Sinead Rees, Helen Vwalika, Bellington Coombs, Robert W Morrow, Rhoda Whittington, William Corey, Lawrence Wald, Anna Celum, Connie |
| description | The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort.
HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4 count >or=250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa. Demographic, behavioral, clinical and laboratory characteristics were assessed.
Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had cohabitated for a median of 5 years (range 2-9) with 28% reporting unprotected sex in the month prior to enrollment. Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-diagnosed sexually transmitted infections were uncommon ( |
| doi_str_mv | 10.1371/journal.pone.0005272 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1290674167</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A473187217</galeid><doaj_id>oai_doaj_org_article_79d969e6768d40fc918b53c4cccaef41</doaj_id><sourcerecordid>A473187217</sourcerecordid><originalsourceid>FETCH-LOGICAL-c690t-140f26462e320e28013e2c14ff07c1643d9de738acf66ea5c3279a3670e30c623</originalsourceid><addsrcrecordid>eNqNk9-KEzEUxgdR3HX1DUQDwoIXU_NnmjReCEtRt7Cw4GpvQzZzpk1JJ7NJRtwH8L1N21E7sheSi4Tkd75z8iWnKF4SPCFMkHcb34dWu0nnW5hgjKdU0EfFKZGMlpxi9vhofVI8i3GTGTbj_GlxQmSFKybpafFzvtZBmwTBxmRNRL5Bl4tlSVBto_Gh1m1Cxvedg4igDd45qJFtkUYpWO32_M2ypCj2XRcgRutblDwKUPcGBq0UdBu3dn_4HqU1oE6H1EKIKKa-vn9ePGm0i_BimM-Kb58-fp1fllfXnxfzi6vScIlTSSrcUF5xCoxioDNMGFBDqqbBwhBesVrWINhMm4Zz0FPDqJCacYGBYcMpOyteH3Q756MaHIyKUIm5qAgXmVgciNrrjeqC3epwr7y2ar_hw0rlyq1xoISsJZfABZ_VuTAjyex2ykxljNHQVCRrfRiy9bdbqA202Qc3Eh2ftHatVv67olwQInAWOB8Egr_rISaVPTTgnG7B91FlTBJBeQbf_AM-fLeBWulcvm0bn7OanaS6qAQjM0HJjpo8QOVRw9aa_Nkam_dHAW9HAZlJ8COtdB-jWtx8-X_2ejlmz4_YNWiX1tG7PuVPFMdgdQBN8DEGaP5YTLDa9cpvN9SuV9TQKzns1fHz_A0amoP9AuOcDlE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1290674167</pqid></control><display><type>article</type><title>Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Lingappa, Jairam R ; Kahle, Erin ; Mugo, Nelly ; Mujugira, Andrew ; Magaret, Amalia ; Baeten, Jared ; Bukusi, Elizabeth A ; Cohen, Craig R ; Katabira, Elly ; Ronald, Allan ; Kiarie, James ; Farquhar, Carey ; Stewart, Grace John ; Makhema, Joseph ; Essex, M ; Were, Edwin ; Fife, Kenneth ; Debruyn, Guy ; Gray, Glenda ; McIntyre, James ; Manongi, Rachel ; Kapiga, Saidi ; Coetzee, David ; Allen, Susan ; Inambao, Mubiana ; Kayitenkore, Kayitesi ; Karita, Etienne ; Kanweka, William ; Delany, Sinead ; Rees, Helen ; Vwalika, Bellington ; Coombs, Robert W ; Morrow, Rhoda ; Whittington, William ; Corey, Lawrence ; Wald, Anna ; Celum, Connie</creator><creatorcontrib>Lingappa, Jairam R ; Kahle, Erin ; Mugo, Nelly ; Mujugira, Andrew ; Magaret, Amalia ; Baeten, Jared ; Bukusi, Elizabeth A ; Cohen, Craig R ; Katabira, Elly ; Ronald, Allan ; Kiarie, James ; Farquhar, Carey ; Stewart, Grace John ; Makhema, Joseph ; Essex, M ; Were, Edwin ; Fife, Kenneth ; Debruyn, Guy ; Gray, Glenda ; McIntyre, James ; Manongi, Rachel ; Kapiga, Saidi ; Coetzee, David ; Allen, Susan ; Inambao, Mubiana ; Kayitenkore, Kayitesi ; Karita, Etienne ; Kanweka, William ; Delany, Sinead ; Rees, Helen ; Vwalika, Bellington ; Coombs, Robert W ; Morrow, Rhoda ; Whittington, William ; Corey, Lawrence ; Wald, Anna ; Celum, Connie ; Partners HSV-2/HIV-1 Transmission Study Team ; for the Partners HSV-2/HIV-1 Transmission Study Team</creatorcontrib><description>The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort.
HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4 count >or=250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa. Demographic, behavioral, clinical and laboratory characteristics were assessed.
Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had cohabitated for a median of 5 years (range 2-9) with 28% reporting unprotected sex in the month prior to enrollment. Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-diagnosed sexually transmitted infections were uncommon (<5%), except for Trichomonas vaginalis in 14% of HIV-1 infected women. Median baseline CD4 count for HIV-1 infected participants was 462cells/mcL and median HIV-1 plasma RNA was 4.2 log(10) copies/mL. After adjusting for age and African region, correlates of HIV-1 RNA level included male gender (+0.24 log(10) copies/mL; p<0.001) and CD4 count (-0.25 and -0.55 log(10) copies/mL for CD4 350-499 and >500 relative to <350, respectively, p<0.001).
The Partners Study successfully enrolled a cohort of 3408 heterosexual HIV-1 serodiscordant couples in Africa at high risk for HIV-1 transmission. Follow-up of this cohort will evaluate the efficacy of acyclovir for HSV-2 suppression in preventing HIV-1 transmission and provide insights into biological and behavioral factors determining heterosexual HIV-1 transmission.
ClinicalTrials.gov NCT00194519.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0005272</identifier><identifier>PMID: 19404392</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Acyclovir ; Acyclovir - administration & dosage ; Adult ; Africa ; AIDS ; Antiretroviral agents ; Antiretroviral therapy ; Antiviral Agents - therapeutic use ; Behavior ; Cancer ; CD4 antigen ; CD4 Lymphocyte Count ; Chlamydia ; Cohort Studies ; Counseling ; Couples ; Demographics ; Disease transmission ; Epidemiology ; Female ; Follow-Up Studies ; Gender ; Gynecology ; Health aspects ; Health risks ; Herpes Genitalis - drug therapy ; Herpesvirus 2, Human ; Heterosexuality ; Highly active antiretroviral therapy ; HIV ; HIV (Viruses) ; HIV Infections - prevention & control ; HIV Infections - transmission ; HIV-1 - genetics ; Hospitals ; Human immunodeficiency virus ; Humans ; Husband and wife ; Infectious diseases ; Infectious Diseases/HIV Infection and AIDS ; Infectious Diseases/Sexually Transmitted Diseases ; Laboratories ; Male ; Medicine ; Obstetrics ; Parasitic diseases ; Product development ; Public health ; Public Health and Epidemiology/Infectious Diseases ; Public Health and Epidemiology/Preventive Medicine ; Recruitment ; Reproductive health ; Ribonucleic acid ; RNA ; RNA, Viral - blood ; Sexual Partners ; Sexually Transmitted Diseases ; STD ; Studies</subject><ispartof>PloS one, 2009-04, Vol.4 (4), p.e5272-e5272</ispartof><rights>COPYRIGHT 2009 Public Library of Science</rights><rights>2009 Lingappa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Lingappa et al. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c690t-140f26462e320e28013e2c14ff07c1643d9de738acf66ea5c3279a3670e30c623</citedby><cites>FETCH-LOGICAL-c690t-140f26462e320e28013e2c14ff07c1643d9de738acf66ea5c3279a3670e30c623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671170/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671170/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19404392$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lingappa, Jairam R</creatorcontrib><creatorcontrib>Kahle, Erin</creatorcontrib><creatorcontrib>Mugo, Nelly</creatorcontrib><creatorcontrib>Mujugira, Andrew</creatorcontrib><creatorcontrib>Magaret, Amalia</creatorcontrib><creatorcontrib>Baeten, Jared</creatorcontrib><creatorcontrib>Bukusi, Elizabeth A</creatorcontrib><creatorcontrib>Cohen, Craig R</creatorcontrib><creatorcontrib>Katabira, Elly</creatorcontrib><creatorcontrib>Ronald, Allan</creatorcontrib><creatorcontrib>Kiarie, James</creatorcontrib><creatorcontrib>Farquhar, Carey</creatorcontrib><creatorcontrib>Stewart, Grace John</creatorcontrib><creatorcontrib>Makhema, Joseph</creatorcontrib><creatorcontrib>Essex, M</creatorcontrib><creatorcontrib>Were, Edwin</creatorcontrib><creatorcontrib>Fife, Kenneth</creatorcontrib><creatorcontrib>Debruyn, Guy</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><creatorcontrib>McIntyre, James</creatorcontrib><creatorcontrib>Manongi, Rachel</creatorcontrib><creatorcontrib>Kapiga, Saidi</creatorcontrib><creatorcontrib>Coetzee, David</creatorcontrib><creatorcontrib>Allen, Susan</creatorcontrib><creatorcontrib>Inambao, Mubiana</creatorcontrib><creatorcontrib>Kayitenkore, Kayitesi</creatorcontrib><creatorcontrib>Karita, Etienne</creatorcontrib><creatorcontrib>Kanweka, William</creatorcontrib><creatorcontrib>Delany, Sinead</creatorcontrib><creatorcontrib>Rees, Helen</creatorcontrib><creatorcontrib>Vwalika, Bellington</creatorcontrib><creatorcontrib>Coombs, Robert W</creatorcontrib><creatorcontrib>Morrow, Rhoda</creatorcontrib><creatorcontrib>Whittington, William</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><creatorcontrib>Wald, Anna</creatorcontrib><creatorcontrib>Celum, Connie</creatorcontrib><creatorcontrib>Partners HSV-2/HIV-1 Transmission Study Team</creatorcontrib><creatorcontrib>for the Partners HSV-2/HIV-1 Transmission Study Team</creatorcontrib><title>Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort.
HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4 count >or=250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa. Demographic, behavioral, clinical and laboratory characteristics were assessed.
Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had cohabitated for a median of 5 years (range 2-9) with 28% reporting unprotected sex in the month prior to enrollment. Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-diagnosed sexually transmitted infections were uncommon (<5%), except for Trichomonas vaginalis in 14% of HIV-1 infected women. Median baseline CD4 count for HIV-1 infected participants was 462cells/mcL and median HIV-1 plasma RNA was 4.2 log(10) copies/mL. After adjusting for age and African region, correlates of HIV-1 RNA level included male gender (+0.24 log(10) copies/mL; p<0.001) and CD4 count (-0.25 and -0.55 log(10) copies/mL for CD4 350-499 and >500 relative to <350, respectively, p<0.001).
The Partners Study successfully enrolled a cohort of 3408 heterosexual HIV-1 serodiscordant couples in Africa at high risk for HIV-1 transmission. Follow-up of this cohort will evaluate the efficacy of acyclovir for HSV-2 suppression in preventing HIV-1 transmission and provide insights into biological and behavioral factors determining heterosexual HIV-1 transmission.
ClinicalTrials.gov NCT00194519.</description><subject>Acquired immune deficiency syndrome</subject><subject>Acyclovir</subject><subject>Acyclovir - administration & dosage</subject><subject>Adult</subject><subject>Africa</subject><subject>AIDS</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral therapy</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Behavior</subject><subject>Cancer</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count</subject><subject>Chlamydia</subject><subject>Cohort Studies</subject><subject>Counseling</subject><subject>Couples</subject><subject>Demographics</subject><subject>Disease transmission</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gender</subject><subject>Gynecology</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Herpes Genitalis - drug therapy</subject><subject>Herpesvirus 2, Human</subject><subject>Heterosexuality</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV (Viruses)</subject><subject>HIV Infections - prevention & control</subject><subject>HIV Infections - transmission</subject><subject>HIV-1 - genetics</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Husband and wife</subject><subject>Infectious diseases</subject><subject>Infectious Diseases/HIV Infection and AIDS</subject><subject>Infectious Diseases/Sexually Transmitted Diseases</subject><subject>Laboratories</subject><subject>Male</subject><subject>Medicine</subject><subject>Obstetrics</subject><subject>Parasitic diseases</subject><subject>Product development</subject><subject>Public health</subject><subject>Public Health and Epidemiology/Infectious Diseases</subject><subject>Public Health and Epidemiology/Preventive Medicine</subject><subject>Recruitment</subject><subject>Reproductive health</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Viral - blood</subject><subject>Sexual Partners</subject><subject>Sexually Transmitted Diseases</subject><subject>STD</subject><subject>Studies</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9-KEzEUxgdR3HX1DUQDwoIXU_NnmjReCEtRt7Cw4GpvQzZzpk1JJ7NJRtwH8L1N21E7sheSi4Tkd75z8iWnKF4SPCFMkHcb34dWu0nnW5hgjKdU0EfFKZGMlpxi9vhofVI8i3GTGTbj_GlxQmSFKybpafFzvtZBmwTBxmRNRL5Bl4tlSVBto_Gh1m1Cxvedg4igDd45qJFtkUYpWO32_M2ypCj2XRcgRutblDwKUPcGBq0UdBu3dn_4HqU1oE6H1EKIKKa-vn9ePGm0i_BimM-Kb58-fp1fllfXnxfzi6vScIlTSSrcUF5xCoxioDNMGFBDqqbBwhBesVrWINhMm4Zz0FPDqJCacYGBYcMpOyteH3Q756MaHIyKUIm5qAgXmVgciNrrjeqC3epwr7y2ar_hw0rlyq1xoISsJZfABZ_VuTAjyex2ykxljNHQVCRrfRiy9bdbqA202Qc3Eh2ftHatVv67olwQInAWOB8Egr_rISaVPTTgnG7B91FlTBJBeQbf_AM-fLeBWulcvm0bn7OanaS6qAQjM0HJjpo8QOVRw9aa_Nkam_dHAW9HAZlJ8COtdB-jWtx8-X_2ejlmz4_YNWiX1tG7PuVPFMdgdQBN8DEGaP5YTLDa9cpvN9SuV9TQKzns1fHz_A0amoP9AuOcDlE</recordid><startdate>20090430</startdate><enddate>20090430</enddate><creator>Lingappa, Jairam R</creator><creator>Kahle, Erin</creator><creator>Mugo, Nelly</creator><creator>Mujugira, Andrew</creator><creator>Magaret, Amalia</creator><creator>Baeten, Jared</creator><creator>Bukusi, Elizabeth A</creator><creator>Cohen, Craig R</creator><creator>Katabira, Elly</creator><creator>Ronald, Allan</creator><creator>Kiarie, James</creator><creator>Farquhar, Carey</creator><creator>Stewart, Grace John</creator><creator>Makhema, Joseph</creator><creator>Essex, M</creator><creator>Were, Edwin</creator><creator>Fife, Kenneth</creator><creator>Debruyn, Guy</creator><creator>Gray, Glenda</creator><creator>McIntyre, James</creator><creator>Manongi, Rachel</creator><creator>Kapiga, Saidi</creator><creator>Coetzee, David</creator><creator>Allen, Susan</creator><creator>Inambao, Mubiana</creator><creator>Kayitenkore, Kayitesi</creator><creator>Karita, Etienne</creator><creator>Kanweka, William</creator><creator>Delany, Sinead</creator><creator>Rees, Helen</creator><creator>Vwalika, Bellington</creator><creator>Coombs, Robert W</creator><creator>Morrow, Rhoda</creator><creator>Whittington, William</creator><creator>Corey, Lawrence</creator><creator>Wald, Anna</creator><creator>Celum, Connie</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20090430</creationdate><title>Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study</title><author>Lingappa, Jairam R ; Kahle, Erin ; Mugo, Nelly ; Mujugira, Andrew ; Magaret, Amalia ; Baeten, Jared ; Bukusi, Elizabeth A ; Cohen, Craig R ; Katabira, Elly ; Ronald, Allan ; Kiarie, James ; Farquhar, Carey ; Stewart, Grace John ; Makhema, Joseph ; Essex, M ; Were, Edwin ; Fife, Kenneth ; Debruyn, Guy ; Gray, Glenda ; McIntyre, James ; Manongi, Rachel ; Kapiga, Saidi ; Coetzee, David ; Allen, Susan ; Inambao, Mubiana ; Kayitenkore, Kayitesi ; Karita, Etienne ; Kanweka, William ; Delany, Sinead ; Rees, Helen ; Vwalika, Bellington ; Coombs, Robert W ; Morrow, Rhoda ; Whittington, William ; Corey, Lawrence ; Wald, Anna ; Celum, Connie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c690t-140f26462e320e28013e2c14ff07c1643d9de738acf66ea5c3279a3670e30c623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Acyclovir</topic><topic>Acyclovir - administration & dosage</topic><topic>Adult</topic><topic>Africa</topic><topic>AIDS</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral therapy</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Behavior</topic><topic>Cancer</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count</topic><topic>Chlamydia</topic><topic>Cohort Studies</topic><topic>Counseling</topic><topic>Couples</topic><topic>Demographics</topic><topic>Disease transmission</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gender</topic><topic>Gynecology</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Herpes Genitalis - drug therapy</topic><topic>Herpesvirus 2, Human</topic><topic>Heterosexuality</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV (Viruses)</topic><topic>HIV Infections - prevention & control</topic><topic>HIV Infections - transmission</topic><topic>HIV-1 - genetics</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Husband and wife</topic><topic>Infectious diseases</topic><topic>Infectious Diseases/HIV Infection and AIDS</topic><topic>Infectious Diseases/Sexually Transmitted Diseases</topic><topic>Laboratories</topic><topic>Male</topic><topic>Medicine</topic><topic>Obstetrics</topic><topic>Parasitic diseases</topic><topic>Product development</topic><topic>Public health</topic><topic>Public Health and Epidemiology/Infectious Diseases</topic><topic>Public Health and Epidemiology/Preventive Medicine</topic><topic>Recruitment</topic><topic>Reproductive health</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Viral - blood</topic><topic>Sexual Partners</topic><topic>Sexually Transmitted Diseases</topic><topic>STD</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lingappa, Jairam R</creatorcontrib><creatorcontrib>Kahle, Erin</creatorcontrib><creatorcontrib>Mugo, Nelly</creatorcontrib><creatorcontrib>Mujugira, Andrew</creatorcontrib><creatorcontrib>Magaret, Amalia</creatorcontrib><creatorcontrib>Baeten, Jared</creatorcontrib><creatorcontrib>Bukusi, Elizabeth A</creatorcontrib><creatorcontrib>Cohen, Craig R</creatorcontrib><creatorcontrib>Katabira, Elly</creatorcontrib><creatorcontrib>Ronald, Allan</creatorcontrib><creatorcontrib>Kiarie, James</creatorcontrib><creatorcontrib>Farquhar, Carey</creatorcontrib><creatorcontrib>Stewart, Grace John</creatorcontrib><creatorcontrib>Makhema, Joseph</creatorcontrib><creatorcontrib>Essex, M</creatorcontrib><creatorcontrib>Were, Edwin</creatorcontrib><creatorcontrib>Fife, Kenneth</creatorcontrib><creatorcontrib>Debruyn, Guy</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><creatorcontrib>McIntyre, James</creatorcontrib><creatorcontrib>Manongi, Rachel</creatorcontrib><creatorcontrib>Kapiga, Saidi</creatorcontrib><creatorcontrib>Coetzee, David</creatorcontrib><creatorcontrib>Allen, Susan</creatorcontrib><creatorcontrib>Inambao, Mubiana</creatorcontrib><creatorcontrib>Kayitenkore, Kayitesi</creatorcontrib><creatorcontrib>Karita, Etienne</creatorcontrib><creatorcontrib>Kanweka, William</creatorcontrib><creatorcontrib>Delany, Sinead</creatorcontrib><creatorcontrib>Rees, Helen</creatorcontrib><creatorcontrib>Vwalika, Bellington</creatorcontrib><creatorcontrib>Coombs, Robert W</creatorcontrib><creatorcontrib>Morrow, Rhoda</creatorcontrib><creatorcontrib>Whittington, William</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><creatorcontrib>Wald, Anna</creatorcontrib><creatorcontrib>Celum, Connie</creatorcontrib><creatorcontrib>Partners HSV-2/HIV-1 Transmission Study Team</creatorcontrib><creatorcontrib>for the Partners HSV-2/HIV-1 Transmission Study Team</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lingappa, Jairam R</au><au>Kahle, Erin</au><au>Mugo, Nelly</au><au>Mujugira, Andrew</au><au>Magaret, Amalia</au><au>Baeten, Jared</au><au>Bukusi, Elizabeth A</au><au>Cohen, Craig R</au><au>Katabira, Elly</au><au>Ronald, Allan</au><au>Kiarie, James</au><au>Farquhar, Carey</au><au>Stewart, Grace John</au><au>Makhema, Joseph</au><au>Essex, M</au><au>Were, Edwin</au><au>Fife, Kenneth</au><au>Debruyn, Guy</au><au>Gray, Glenda</au><au>McIntyre, James</au><au>Manongi, Rachel</au><au>Kapiga, Saidi</au><au>Coetzee, David</au><au>Allen, Susan</au><au>Inambao, Mubiana</au><au>Kayitenkore, Kayitesi</au><au>Karita, Etienne</au><au>Kanweka, William</au><au>Delany, Sinead</au><au>Rees, Helen</au><au>Vwalika, Bellington</au><au>Coombs, Robert W</au><au>Morrow, Rhoda</au><au>Whittington, William</au><au>Corey, Lawrence</au><au>Wald, Anna</au><au>Celum, Connie</au><aucorp>Partners HSV-2/HIV-1 Transmission Study Team</aucorp><aucorp>for the Partners HSV-2/HIV-1 Transmission Study Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2009-04-30</date><risdate>2009</risdate><volume>4</volume><issue>4</issue><spage>e5272</spage><epage>e5272</epage><pages>e5272-e5272</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The Partners HSV-2/HIV-1 Transmission Study (Partners Study) is a phase III, placebo-controlled trial of daily acyclovir for genital herpes (HSV-2) suppression among HIV-1/HSV-2 co-infected persons to reduce HIV-1 transmission to their HIV-1 susceptible partners, which requires recruitment of HIV-1 serodiscordant heterosexual couples. We describe the baseline characteristics of this cohort.
HIV-1 serodiscordant heterosexual couples, in which the HIV-1 infected partner was HSV-2 seropositive, had a CD4 count >or=250 cells/mcL and was not on antiretroviral therapy, were enrolled at 14 sites in East and Southern Africa. Demographic, behavioral, clinical and laboratory characteristics were assessed.
Of the 3408 HIV-1 serodiscordant couples enrolled, 67% of the HIV-1 infected partners were women. Couples had cohabitated for a median of 5 years (range 2-9) with 28% reporting unprotected sex in the month prior to enrollment. Among HIV-1 susceptible participants, 86% of women and 59% of men were HSV-2 seropositive. Other laboratory-diagnosed sexually transmitted infections were uncommon (<5%), except for Trichomonas vaginalis in 14% of HIV-1 infected women. Median baseline CD4 count for HIV-1 infected participants was 462cells/mcL and median HIV-1 plasma RNA was 4.2 log(10) copies/mL. After adjusting for age and African region, correlates of HIV-1 RNA level included male gender (+0.24 log(10) copies/mL; p<0.001) and CD4 count (-0.25 and -0.55 log(10) copies/mL for CD4 350-499 and >500 relative to <350, respectively, p<0.001).
The Partners Study successfully enrolled a cohort of 3408 heterosexual HIV-1 serodiscordant couples in Africa at high risk for HIV-1 transmission. Follow-up of this cohort will evaluate the efficacy of acyclovir for HSV-2 suppression in preventing HIV-1 transmission and provide insights into biological and behavioral factors determining heterosexual HIV-1 transmission.
ClinicalTrials.gov NCT00194519.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>19404392</pmid><doi>10.1371/journal.pone.0005272</doi><tpages>e5272</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2009-04, Vol.4 (4), p.e5272-e5272 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1290674167 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Acquired immune deficiency syndrome Acyclovir Acyclovir - administration & dosage Adult Africa AIDS Antiretroviral agents Antiretroviral therapy Antiviral Agents - therapeutic use Behavior Cancer CD4 antigen CD4 Lymphocyte Count Chlamydia Cohort Studies Counseling Couples Demographics Disease transmission Epidemiology Female Follow-Up Studies Gender Gynecology Health aspects Health risks Herpes Genitalis - drug therapy Herpesvirus 2, Human Heterosexuality Highly active antiretroviral therapy HIV HIV (Viruses) HIV Infections - prevention & control HIV Infections - transmission HIV-1 - genetics Hospitals Human immunodeficiency virus Humans Husband and wife Infectious diseases Infectious Diseases/HIV Infection and AIDS Infectious Diseases/Sexually Transmitted Diseases Laboratories Male Medicine Obstetrics Parasitic diseases Product development Public health Public Health and Epidemiology/Infectious Diseases Public Health and Epidemiology/Preventive Medicine Recruitment Reproductive health Ribonucleic acid RNA RNA, Viral - blood Sexual Partners Sexually Transmitted Diseases STD Studies |
| title | Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T15%3A27%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20of%20HIV-1%20discordant%20couples%20enrolled%20in%20a%20trial%20of%20HSV-2%20suppression%20to%20reduce%20HIV-1%20transmission:%20the%20partners%20study&rft.jtitle=PloS%20one&rft.au=Lingappa,%20Jairam%20R&rft.aucorp=Partners%20HSV-2/HIV-1%20Transmission%20Study%20Team&rft.date=2009-04-30&rft.volume=4&rft.issue=4&rft.spage=e5272&rft.epage=e5272&rft.pages=e5272-e5272&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0005272&rft_dat=%3Cgale_plos_%3EA473187217%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1290674167&rft_id=info:pmid/19404392&rft_galeid=A473187217&rft_doaj_id=oai_doaj_org_article_79d969e6768d40fc918b53c4cccaef41&rfr_iscdi=true |